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ABSTRACT 
BACKGROUND:  Tramadol, acentrally acting analgesic drug, can be administered 
via multiple routes and is generally well tolerated. 
OBJECT IVE:  This study was designed to assess the pharmacokinetics of epidural 
tramadol administered preoperatively in Japanese patients undergoing upper abdomi- 
nal surgery. 
METHOD:  Japanese patients who were scheduled to undergo upper abdominal 
surgery in The Kitasato Institute Hospital, Tokyo, Japan, were included. Patients 
received tramadol 2 mg/kg with 5 mL of 1% mepivacaine epidurally 10 minutes before 
incision. The serum concentration of tramadol was determined by high-performance 
liquid chromatography for 21 hours after administration. Serum concentration was 
determined before tramadol administration and 10, 20, 30, and 60 minutes after tra- 
madol administration, first postoperative night, and first postoperative day. Pain 
score and adverse vents (AEs) were assessed at 1, 3, 6, 12, 18, 24, 36, and 48 hours after 
surgery by patient interview. 
RESULTS:  Eleven patients were assessed for enrollment. Seven patients (6 men, 
1 woman; mean [SD] age, 61.3 [12.6] years; mean [SD] weight, 59.9 [8.9] kg) pro- 
vided consent and completed the study. The mean (SD) serum C .... of tramadol was 
1385.5 (390.8) ng/mL, T .... was 0.33 (0.22) hour, and terminal elimination half-life 
(tl/2[ 3) was 10.5 (2.3) hours. Four patients complained of nausea; however, only 
1 patient was administered an antiemetic. No other AEs were reported. 
CONCLUSION:  This pilot study found that epidural tramadol administered 
before incision induced a Cma ~ within 30 minutes of administration. The drug was 
detected in serum at -21 hours after surgery. (Cuff Ther Res C/in Exp. 2008;69:49 55) 
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INTRODUCTION 
Tramadol, a centrally acting analgesic agent with la-opioid agonist properties, inhibits 
noradrenaline uptake and causes erotonin release. 1 It can be administered IV, IM, PO, 
parenterally, and rectally for pain control and is generally well tolerated. 2 Therefore, 
tramadol might be a useful alternative to opioid analgesics for the treatment of patients 
with moderately severe, acute, or chronic pain. 
Some opioids are administered epidurally with local anesthesia s postoperative 
analgesia. Several studies have reported that epidural tramadol provided postoperative 
analgesia nd was well tolerated, but pharmacokinetic data of epidural tramadol have 
not been widely reported. 3 5 One study reported the pharmacokinetics of tramadol 
administered epidurally in children. 6
The present study was designed to assess the pharmacokinetics of epidural tramadol 
administered preoperatively in Japanese patients undergoing upper abdominal surgery. 
PAT IENTS AND METHODS 
PAT IENTS 
The study was approved by the ethics committee of The Kitasato Institute, Tokyo, 
Japan. Consecutive Japanese patients who were scheduled to undergo upper abdominal 
surgery in the Kitasato Institute Hospital were included in this study. They were in- 
formed in detail about the purpose of the study and gave written informed consent. 
Exclusion criteria included any severe disease complications (eg, abnormal hematology 
or biochemistry findings), diabetes mellitus, neuropathies, and major surgical procedures. 
The anesthetist allocated the patients to treatment. The nurses and pharmacists 
who measured the patients' pain scores and the surgeons who ordered analgesia for 
postoperative pain were blinded to the medication administered. 
ANESTHESIA  REGIMEN 
An epidural catheter was inserted between T5 and T10. Ten minutes before inci- 
sion, tramadol 2 mg/kg with 5 mL of 1% mepivacaine was injected via the epidural 
catheter. Anesthesia was induced with thiopental sodium or propofol. Tracheal in- 
tubation was facilitated with succinylcholine chloride or vecuronium bromide and 
maintained with oxygen, nitrous oxide, and sevoflurane. After surgery, 0.25 % bupi- 
vacaine hydrochloride was administered epidurally for 48 hours via an infuser. 
BLOOD SAMPL ING 
Venous blood samples (5 mL) were drawn for analysis of serum tramadol concen- 
tration before tramadol administration and 10, 20, 30, and 60 minutes after tramadol 
administration, immediately after closure, during the first postoperative night, and 
for 1 postoperative day (mean 21 hours). The samples were centrifuged immediately 
at 3000 rpm and serum was frozen at 80°C until analysis. 
SERUM ANALYS IS  
Tramadol hydrochloride was provided by Nippon Shinyaku Company Ltd. (Tokyo, 
Japan) and metoprolol tartrate as internal standard was from SIGMA (Tokyo, Japan). 
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The high-performance liquid chromatography s stem consisted of a model LC-9A 
constant flow solvent delivery pump, a model SPD-10A vp ultraviolet detector, and a 
model CTO- 10AS vp column oven (Shimadzu Corporation, Kyoto, Japan). The detec- 
tion wavelength was 225 nm. The analysis and assay of tramadol were performed by 
warming the reverse-phase column (Mightysil RP-8 GP 150 x 4.6 mm, particle size 
5 pm, Kanto Chemical Co., Ltd., Tokyo, Japan) to 40°C. A mixture of 0.1 M phosphate 
bufter (pH 3.5) and acetonitrile (90:10) was employed as the analytic mobile phase at 
a flow rate of 1.2 mL/min. 
First, 75 pL of metoprolol 10 pg/mL was added to 1.0 mL of serum sample. This 
solution was stirred in a vortex mixer. The pH was adjusted to 12 with sodium 
hydroxide 0.1 M. Six milliliters of ethyl acetate were added and then mixed and cen- 
trifuged at 3000 rpm for 15 minutes. After the organic phase was transferred to a 
glass tube, it was evaporated at40°C. The residue was reconstituted with 200 ilL of 
mobile phase, and 100-tlL aliquots were injected after the solution was siphoned 
through a 0.1-pm filter] 
ADVERSE EVENTS 
The nurses and pharmacists asked the patients about any adverse events (AEs) 
when they monitored the patient's pain score. Spontaneously reported AEs were also 
recorded. 
STAT IST ICAL  ANALYS IS  
Serum data were analyzed using nonlinear egression analysis. The analysis was 
performed with PSAG-CP (ASMedica, Osaka, Japan) using a 2-compartment model. 
Interval data were described as mean (SD). 
RESULTS 
Eleven patients were assessed for enrollment. Seven patients (6 men, 1 women; mean 
[SD] age, 61.3 [12.6] years; mean [SD] weight, 59.9 [8.9] kg) provided written consent 
and were included in the study (Table I). 
Nonlinear regression analysis gave calibration curves with a correlation coeffi- 
cient of 0.999 (0.001) (N 7) for tramadol (0 2000 ng/mL). Tramadol was re- 
covered quantitatively at 93.4%. Assays for within-run and day-to-day reproduci- 
bility gave CVs of 9.7% (n 8) and 1.0% (n 5), respectively, at concentrations 
of 500 ng/mL. The detection l imit for quantif ication of this assay method was 
5.0 ng/mL. 
Mean (SD) serum tramadol concentrations were 0, 1083.8 (472.6), 1278.0 (363.0), 
1228.0 (458.1), 770.3 (145.8), 586.0 (107.2), 437.6 (81.5), 347.1 (70.1), and 
155.3 (32.3) ng/mL at 0, 0.19, 0.34, 0.5, 1.11, 2.85, 5.67, 10.36, and 21.20 hours 
after administration, respectively (Figure). T .... was 0.33 (0.22) hour, C .... was 
1385.5 (390.8) ng/mL, and terminal elimination half-life (t1/213) was 10.5 (2.3) hours 
(Table II). 
Four patients complained of nausea; however, only 1 patient was administered an 
antiemetic. No other AEs were reported. 
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Table I. Baseline demographic and clinical characteristics in Japanese 
patients undergoing upper abdominal surgery (N = 7). 
Variable Value 
Age, mean (SD), y 
Sex ratio, male/female 
Weight, mean (SD), kg 
Tramadol dose,* mean (SD), mg 
Duration of surgery, mean (SD), h 
Type of surgery, no, 
Total gastrectomy 
Partial gastrectomy 
Cholecystectomy 
Hepatectomy 
61.3 (12.6) 
6/1 
59.9 (8.9) 
119.0 (15.8) 
2.9 (0.6) 
*Dose = 2 mg/kg. 
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Figure. Mean (SD) serum tramadol concentrations after epidural administration of 2 mg/kg 
before incision in Japanese patients undergoing upper abdominal surgery (N = 7). 
52 
R.  KUBOTA ET  AL .  
Table II. The pharmacokineUc parameters of tramadol in Japanese 
patients undergoing upper abdominal surgery (N = 7). Data 
are mean (SD). 
Parameter Value 
AUCo_~, ng/mL • h -1 10322.8 (1801.6) 
Cmax, ng/mL 1385.5 (390.8) 
Tmax, h 0.33 (0.22) 
tl/2c~, h 0.30 (0.12) 
tl/213, h 10.5 (2.3) 
Kel, h -1 0.24 (0.12) 
AUC 0 ~ = area under  the blood concent ra t ion - t ime curve from 0 to infinity; tl/2c ~ = 
initial decay half-life; tl/213 = terminal  el iminat ion half-life; Kel = el iminat ion rate. 
DISCUSSION 
In a study of men and dogs by Naraba et al, 8 serum tramadol concentrations were reported 
to be 1040 and 860 ng/mL, respectively, at 30 minutes after administration. The 
serum concentrations decreased gradually when 2 healthy volunteers were adminis- 
tered tramadol 100 mg (1.65 mg/kg) IM. In a study by Lintz et al, 9 mean (SD) C .... was 
308 (89) ng/mL, Tm~ xwas 1.20 (0.39) hours, and tl/213 was 5.5 (0.9) hours when trama- 
dol 100 mg was administered PO to 8 healthy volunteers. A second study by Lintz 
et al 1° found C .... was 422 to 718 ng/mL, Tax  was 0.25 to 1.00 hours, and tl/213 was 
5.2 hours when tramadol 100 mg was administered IV to 8 normal volunteers. 
Baraka et al 4 reported that epidural tramadol or morphine could be used to provide 
prolonged postoperative analgesia, and tramadol was well tolerated. 11 Epidural trama- 
dol has been evaluated as a postoperative analgesic since 1991, but there have been 
few reports on the pharmacokinetics of tramadol. Shimizu et a111 reported that the 
analgesic effect was not sufficient when 1 mg/kg of tramadol was administered epi- 
durally. Thus, 2 mg/kg of epidural tramadol was administered to patients undergo- 
ing upper abdominal surgery in this study, and the pharmacokinetics of tramadol were 
evaluated. 
In this study, epidural administration of tramadol 2 mg/kg before incision was 
associated with a mean (SD) peak serum tramadol concentration of 1385.5 (390.8) ng/mL 
within 30 minutes. The mean (SD) tl/2[ 3 was 10.5 (2.3) hours, and some serum concen- 
trations remained until -21 hours after administration. Cma ~ was numerically higher, and 
tl/2 appeared longer than those observed with other routes of administration. 8 10 The 
action of tramadol is thought to be at the spinal level, similar to other opiates (eg, 
morphine). Tramadol is absorbed immediately into the epidural veniplex after epidu- 
ral administration because tramadol has a high tissue affinity 12 and is distributed to 
serum. The minimum eftective tramadol serum concentration for postoperative anal- 
gesia is not known. However, Lehmann et a113 suggested that serum tramadol concen- 
trations >300 ng/mL seem necessary to reach the therapeutic window for analge- 
sia. The serum concentration of tramadol was maintained at about one tenth of the 
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peak serum concentration, between 109.1 and 213.0 ng/mL, up to 21 hours after 
surgery in this study. This suggests that tramadol continued to be distributed to the 
serum from the epidural veniplex. 
Tramadol is metabolized by cytochrome P450 2D6 (CYP2D6) or sparteine oxy- 
genase to 11 metabolites. 14The 0-desmethyl metabolite (M1) of tramadol has 2 to 
4 times the analgesic potency than the parent compound, and 4 to 200 times greater 
affinity for the p-receptor than the parent compound. 2 Additionally, the (+) enantio- 
mer of tramadol and its metabolites bind more strongly to the g-receptor than the 
(-) enantiomer. The mean elimination half-life of tramadol reported after PO or IV 
administration is 5 to 6 hours in healthy volunteers. 2 Approximately 30% of tramadol 
is excreted in the urine as an unchanged form and -60% is excreted as metabolites. 1 
One third of the dose is metabolized to the 0-desmethyl metabolite (+) and (-) M1 by 
CYP2D6.15 This enzyme has genetic polymorphism. Therefore, it is important o 
discuss the pharmacokinetics of the active metabolites and the enantiomers of trama- 
dol in the future. We should also investigate the influence of the CYP2D6 genotype. 
Additionally, we should evaluate the efficacy and safety of tramadol administered 
epidurally before incision. 
CONCLUSION 
This pilot study found that epidural tramadol administered before incision induced a 
C .... within 30 minutes of administration. The drug was detected in serum at -21 hours 
after surgery. 
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